Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
P/B ratio for Amicus Therapeutics, Inc. (FOLD)
P/B ratio as of 2023: 26.15
According to Amicus Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 26.15. At the end of 2022 the company had a P/B ratio of 28.68.
P/B ratio history for Amicus Therapeutics, Inc. from 2003 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 26.15 |
| 2022 | 28.68 |
| 2021 | 10.20 |
| 2020 | 20.87 |
| 2019 | 4.92 |
| 2018 | 5.19 |
| 2017 | 6.25 |
| 2016 | 1.85 |
| 2015 | 3.07 |
| 2014 | 5.07 |
| 2013 | 2.63 |
| 2012 | 1.76 |
| 2011 | 4.02 |
| 2010 | 2.01 |
| 2009 | 1.25 |
| 2008 | 2.53 |
| 2007 | 1.38 |
| 2006 | -0.14 |
| 2005 | -0.17 |
| 2004 | 0.00 |
| 2003 | -0.84 |